Alectinib, a next-generation ALK inhibitor (ALKi), is also known to exhibit a high antitumor activity for pts with ALK+ NSCLC, i.e., RR and PFS of 93.5 % and 27.7 months, respectively [7]. Here, ALK is linked to non-small cell lung carcinoma.